Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 516

2.

Managing acute coronary syndrome: evidence-based approaches.

Spinler SA.

Am J Health Syst Pharm. 2007 Jun 1;64(11 Suppl 7):S14-24.

PMID:
17519441
3.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
4.

New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.

Spinler SA, Hilleman DE, Cheng JW, Howard PA, Mauro VF, Lopez LM, Munger MA, Gardner SF, Nappi JM.

Ann Pharmacother. 2001 May;35(5):589-617. Review.

PMID:
11346067
5.

Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.

Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, Pollack CV Jr; CRUSADE Investigators.

J Thromb Thrombolysis. 2006 Jun;21(3):211-20.

PMID:
16683212
6.

[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].

Galli M, Maggioni AP, Vassanelli C, Tavazzi L.

Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian.

PMID:
10731377
7.

Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).

Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ; National Registry of Myocardial Infarction-4.

Am J Cardiol. 2006 Nov 1;98(9):1125-31. Epub 2006 Aug 31.

PMID:
17056312
8.

Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.

Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC.

Catheter Cardiovasc Interv. 2010 Oct 1;76(4):513-24. doi: 10.1002/ccd.22546.

PMID:
20882655
9.

Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.

Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson ED; CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators.

Circulation. 2006 Sep 26;114(13):1380-7. Epub 2006 Sep 18.

10.
11.

Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG.

Chest. 2008 Jun;133(6 Suppl):670S-707S. doi: 10.1378/chest.08-0691.

PMID:
18574276
12.

Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV Jr, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW; Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators.

JACC Cardiovasc Interv. 2008 Dec;1(6):639-48. doi: 10.1016/j.jcin.2008.10.004.

13.

Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.

Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S.

Clin Cardiol. 2008 Mar;31(3 Suppl 1):I2-9. doi: 10.1002/clc.20362. Review. Erratum in: Clin Cardiol. 2009 Feb;32(2):111.

14.

Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.

Savonitto S, Ambrosini V, Marzocchi A, Tolaro S, Petronio AS, Galassi AR, Bongo AS, Gaglione A, Bolognese L; IDEA Survey Investigators; Italian Society of Invasive Cardiology.

Ital Heart J. 2005 Feb;6(2):106-18.

PMID:
15819503
15.

Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.

Marsh JD.

Am J Health Syst Pharm. 2002 Nov 1;59(21 Suppl 7):S15-26. Review.

PMID:
12434711
16.

Triple antiplatelet therapy in acute coronary syndromes.

Valgimigli M, Minarelli M.

Drugs. 2011 Sep 10;71(13):1703-19. doi: 10.2165/11594100-000000000-00000. Review.

PMID:
21902293
17.
18.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

19.
20.

Supplemental Content

Support Center